7. Method of stem-cell collection from the donor will be at the discretion of the treating physician. Although it is anticipated that majority of patients will receive allograft mobilized with G-CSF alone; however donors receiving allografts mobilized with experimental agents (e.g. plerixafor) will remain eligible for the study.